Zucker rats, thereby implicating the hypothalamopituitary-adrenal axis in the pathogenesis of obesity. In this study glucose-induced insulin secretion and glucokinase activity were investigated in isolated islets from adrenalectomized and control obese and lean female rats. Islets from control fa/fa rats were more sensitive to glucose with a half-maximal effective concentration (ECs0) of 6.1 + 2.0 mmol. 1-1 compared with 10.6 + 2.7 mmol. 1-1 for adrenalectomized fa/fa rat islets. Adrenalectomy did not alter the islet sensitivity to glucose in the lean rats (ECs0 of 9.4+1.5mmo1.1-1 and 9.3+2.0mmo1-1-1 for adrenalectomized and control lean rats respectively). Mannoheptulose did not inhibit insulin secretion from control obese rats; however at concentrations of 1.0 mmol 9 1-1 or more it significantly inhibited glucose-induced insulin secretion in adrenalectomized obese and lean, and control lean rat islets (p < 0.05).
cose, increasing at high glucose levels and decreasing at low glucose levels both in vivo [12] and in vitro [13, 14] . Failure of the insulin response to adapt to changes in ambient glucose is reported in starved adult fa/fa rats in vitro [9] and in vivo [15] . Furthermore, fa/fa rats exhibit fasting hyperinsulinaemia despite having blood glucose levels similar to lean rats [6] . Mannoheptulose (MH), which competitively inhibits glucokinase to block glucose-induced insulin release [16] , is found to have a reduced effect on insulin secretion in isolated islets from adult and weanling fa/fa rats [9, 17] , a phenomenon also reported in other genetically obese rodents, including corpulent (cp/cp) rats [18] . These changes in insulin secretory regulation may reflect early defects in pancreatic islet glucokinase function.
Adrenalectomy (ADX), when performed before weaning, prevents development of all hormonal, metabolic and behavioural abnormalities including hyperinsulinaemia in fa/fa rats [19, 20] and these same abnormalities are partially reduced when ADX is carried out in adult rats [21, 22] . The effects of ADX are reversed by glucocorticoid replacement [20, 22] . The mechanism by which ADX normalizes or reduces insulin secretion is still not clear; however, reduced food intake [21, 23] , or removal of the inhibitory effect of corticosterone on the autonomic nervous system activity to the endocrine pancreas [20] may both play crucial roles. We considered that ADX might prevent hyperinsulinaemia by altering glucose metabolism within the beta cells and decided to study glucokinase function because of its glucose sensing role and known abnormalities in fa/fa rats. In this study we investigated the effects of ADX on glucose-induced insulin secretion, MH inhibitory action and glucose phosphorylation in isolated islets from lean and fa/fa rats. Weanling lean and fa/fa rats were adrenalectomized, then 2 weeks after surgery the glucokinase activity and insulin secretory response to glucose and MH were compared to sham-operated controls.
Materials and methods
Animals. Four-week-old female Zucker lean and obese rats were obtained from Charles River Laboratories (St. Constant, Quebec, Canada) and housed four animals per cage according to their phenotype. They were maintained in an artificially lit room with a 12-h dark, 12-h light cycle and a constant temperature of 22~ before and after they were either adrenaleetomized or sham-operated at 5 weeks of age. They were fed commercial rodent laboratory chow 5001 (Purina, St. Louis, Mo., USA) and tap water ad libitum. After surgery they were also given a NaC1/glucose solution (154 mmol-1-1 NaC1 and 40 mg. 1-1 glucose) to drink ad libitum.
ADX. Animals were fasted overnight and then weighed before surgery. They were anaesthetized i.p. using a mixture of sodium pentobarbital (65 mg. ml 1) (MTC Pharmaceuticals, 191 Mississauga, Ont., Canada) and diazepam (5 rag. m1-1) (Sabex Inc, Boucherville, Quebec, Canada) in 154 retool. 1-1 NaC1 at a dose of 0.10-0.15 ml. 100 g body weight -1. Animals were either bilaterally adrenalectomized or sham-operated (and referred to as "control") using the ventral approach [22] . After 15 days solid food was removed from the cages overnight but the rats continued to have access to glucose/NaC1 solution and water. Before the pancreas was removed, the animals were weighed and 0.5-1.0-ml blood samples were collected in heparinized tubes from the tail vein of freely moving conscious rats. Plasma was collected by centrifugation and stored at -20 ~ for corticosterone and glucose determination (glucose oxidase method; Beckman Glucose Analyser II, Fullerton, Calif., USA). Animals that had no residual pieces of adrenal gland and with decreased serum corticosterone levels were considered to be completely adrenalectomized and were included in the analyses.
Islet isolation and culture. After blood was collected, the animals were anaesthetized i.p. with sodium pentobarbital (65 rag. kg body weight-I). Islets from ADX and control rats were isolated by a modification of the method of Van Der Vliet et al. [24] as described by Kibenge and Chan [17] . The islets were cultured overnight in Dulbecco's modified Eagle's medium (DMEM) (Gibco/BRL Canada Inc, Burlington, Ontario, Canada) supplemented with 1% antibiotic/antimycotic solution, 10 mmol-1-1 4-(2-hydroxyethyl)-l-piperazineethanesulphonic acid (Hepes) (Sigma Chemical Co, St. Louis, Mo., USA), 12.5 retool-1-1 glucose and 10% calf serum (Gibco/ BRL). By culturing overnight under standard conditions, immediate or short-term effects of the obese environment on islet function should be removed, leaving us able to study relatively persistent or long-term changes in insulin secretory regulation. Although culturing in various glucose conditions can result in changes in glucokinase function, conditions similar to those employed here in fact resulted in no significant changes in glucokinase kinetic parameters compared with freshly isolated islets, even when the culture period was as long as 7 days [14] .
Insulin release and measurement. After overnight incubation, the culture medium was replaced with 1.0ml of fresh DMEM containing various glucose concentrations ranging from 0 to 25 retool. 1-1 and 0.1% gelatin (Gibco/BRL). M (Sigma) (0.10-100 mmol. 1-1) was added to the islet samples containing 5.5-25.0 mmol. 1-1 glucose, which were then statically incubated for 90 rain at 37 ~ (95 % air, 5 % CO2, saturated with water vapour). The supernatant was collected by aspiration and stored until assayed. To measure the total insulin content of the islets, the islet pellet was boiled in 3 % acetic acid and then stored at -20 ~ until assayed. Immunoreactive insulin was measured using a radioimmunoassay employing z25I-porcine insulin as the tracer and rat insulin as the standard, with a sensitivity range of 37.5-1200 pmol 9 1-1. The insulin antiserum (Gp 01, raised in guinea pigs) was a gift from Dr. R.A. Pederson (University of British Columbia, Vancouver, B. C., Canada). Due to variability in pancreatic islet size, mostly from obese rats [6] , insulin release was routinely expressed as a percent of total islet insulin content. The half-maximal glucose concentrations (ECs0) were calculated using Corticosterone radioimmunoassay. Measurement of total serum corticosterone levels was carried out according to the kit manufacturer's manual (ICN Biomedical Inc., Montreal, Quebec, Canada). Glucose phosphorylating activity. Two weeks after surgery, islets from control and ADX rats were isolated and cultured as described above. The following day, batches of 25-30 islets were washed in glucokinase assay buffer containing 0.05 mmol. 1-1 glucose. The assay buffer was Krebs-Ringer bicarbonate supplemented with 10mmol. 1 -~ Hepes (pH 7.4), 5 mmol. 1-1 MgATR 10 mmol. 1 -~ NaF, and glucose from 0.05-16 mmol 9 1-1. After pelleting by centrifugation, the islets were re-suspended in 225 ~1 of assay buffer, containing glucose and other reagents as specified, and subjected to three freezethaw cycles at -70~ At zero time, o-[UJ4C]glucose (250 mCi mmol. 1-1; Amersham, Oakville, Ont., Canada) was added and the disrupted islets incubated for 20 rain at 37 ~ The reaction was terminated by adding 30 ~1 0.25 mol-1-1 EDTA in 2 tool. 1-1 glucose, and duplicate 60-~tl samples were subsequently spotted on diethylaminoethyl (DEAE) cellulose filters (Whatman DE-81; VWR Scientific, Toronto, Ont., Canada) that retain phosphoric esters [25] . The radioactivity retained on the washed and dried filters was counted by liquid scintigraphy. The protein content of the remaining sample was determined by the Lowry method, using bovine serum albumin as standard. Samples without islet tissue served as blank controls. To determine hexokinase (ATP: D-glucose 6-phosphotransferase, EC 2.7.1.1) activity, glucose concentrations from 0.05-0.50 mmol. 1 1 were used while 6.0-16.0 retool-1 1 glucose was used for glucokinase (ATP: D-glucose 6-phosphotransferase, EC 2.7.1.2) activity measurement. Velocities were calculated after correcting for specific activity and normalized by comparing to islet protein (Lowry method, Sigma). For glucokinase, values were corrected for hexokinase activity by subtracting VHEXOK~ASZ at 0.5 mmol. 1 -a glucose. Kinetic parameters were estimated from Eadie-Hofstee analysis of the data.
Statistical analysis
Data are expressed as mean + SEM and (n) refers to the number of animals from which islets were isolated. Each data point is an average of duplicate samples from one animal. The insulin secretion data were analysed using two-way analysis of variance (general linear model) after arcsine transformation [26] of the actual percent data shown in the figures, when testing for interactions between MH concentrations and experimental variables such as age, phenotype, and ADX. One-way analysis of variance was used when comparing effects of different doses of test drugs within phenotypes using Minitab version 7.1 (Minitab Inc., State College, Pa., USA), which was followed by the Student-Newman-Keuls test. The unpaired t-test was used when comparing responses produced by the same treatment between phenotypes or between ADX and control rats of the same phenotype. Statistically significant differences (p < 0.05) in K m or Vma X of glucokinase were determined using the general linear model followed by Student-Newman-Keuls test. All results were considered significant at p < 0.05.
Results

Characteristics of ADXrats.
Body weight, plasma corticosterone, and islet insulin content were compared in ADX and control rats (Table 1) . Corticosterone levels were reduced by over 90 % in both ADX lean and ADXfa/fa rats. In control rats there was no phenotype difference in the plasma levels of corticosterone. The hormone levels in the control rats of both phenotypes were higher than those previously reported in normal rats [27] , which might have been due to the stress of fasting and blood collection procedures.
ADX did not have any significant effect on the islet insulin content in either phenotype (p = 0.656), although ADXfa/fa rats had 25 % less pancreatic insulin content compared with control fa/fa rats when the data were expressed as insulin content per microgram islet protein. Obese ADX and control rats had more than two times more islet insulin content compared with the lean groups both before [17] and 2 weeks post-surgery. There was no effect of either phenotype or ADX on plasma glucose levels (p = 0.237). These glucose concentrations were higher than those measured after fasting because, although solid food had been removed, the animals still had access to the NaC1/glucose solution.
Obese rats weighed more than lean rats at ages 5 weeks (before ADX) and 7 weeks (15 days postsurgery). Comparison of both control and ADX groups at 5 and 7 weeks of age showed a significant effect due to both ADX and age. Within phenotype comparison showed that while ADX did not affect the weight gain pattern in lean rats, it slowed weight gain by 11% infa/fa rats (p < 0.05).
Effects of ADX on insulin secretion. The effects of increasing glucose concentration on insulin secretion from islets of ADX and control lean and fa/fa rats were measured (Fig. 1) and ECs0 values were calculated. In lean ADX and control rats (n = 10 each) there was no significant difference in the calculated ECs0 (9.4 + 1.5 mmol. 1-1 and 9.3 + 2.0 mmol. 1-1, respectively). For ADX fa/fa islets (n = 8) the ECs0 for glucose was 10.6 + 2.7 mmol. 1-1, while in the islets of control fa/fa rats (n=8) an ECs0 of 6.1 _+ 2.0 mmol -1 1 was calculated (p < 0.05), indicating reduced glucose sensitivity in the ADX fa/fa islets. In order to facilitate comparisons with other studies, and to demonstrate the absolute magnitude of change in insulin secretion induced by ADX, estimates of absolute insulin secretory values per islet are given in Table 2 . However, the wide range of values obtained, which is due to considerable variation in islet size and hence insulin content, precludes the use of absolute insulin concentrations to calculate ECs0 values.
Glucose ( Fig.2 ). An effect of ADX on MH inhibition of glucose-induced insulin release was observed only in pancreatic islets offa/fa rats, where MH inhibited insulin secretion in a dosedependent manner (21.8-53.2 %). In isolated islets from control fa/fa rats MH did not produce any significant reduction in glucose-induced insulin release (p > 0.05) (Fig. 2B) . The 1.0 mmol. 1-1 MH concentration produced only a 5 % reduction in insulin secretion by pancreatic islets from control fa/fa rats compared with a 48 % reduction in control lean rats.
Thus, ADX increased the sensitivity of the fa/fa rat beta cells to MH inhibitory actions within 2 weeks of surgery.
Since 15 mmol. 1-1 glucose induces maximal stimulation offa/fa rat beta ceils, we wanted to find out if MH would inhibit insulin secretion if sub-maximal glucose concentrations were used (Fig.3) . Glucoseinduced insulin release in the presence of 5.5 mmol. 1-1 glucose was not significantly (p < 0.05) inhibited with any MH concentrations used in isolated islets from either control or ADX rats of both phenotypes (data not shown). MH (1-100 mmol. 1 2) inhibitory action was varied in the presence of 8.3 mmol -1-1 glucose. While there was no significant inhibition (p > 0.05) in either control and ADX obese rat islets, 30 and 100 mmol. i -1 MH produced a significant re- Effect of ADX on glucokinase activity. Glucose phosphorylating activity of disrupted islet preparations was measured 2 weeks after ADX or sham surgery. As shown in Figure 4 , ADX significantly reduced the total phosphorylation of glucose (hexokinase + Data are the means + SEM or (range of values) for the number of experiments reported in Figure 1 
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.~1o g Fig.2A , B. Effect of ADX on MH (0.1-100 mmol. 11) action in isolated islets from ADX (m) and control (,) rats. A Lean control (n = 7) and ADX (n = 6) islets; B obese control (n = 7) and ADX (n = 6) islets. Insulin secretion was stimulated by 15 mmol 9 1-1 glucose. *p < 0.05 compared to the glucose control for each group. **p < 0.05 ADX compared to control fa/fa rats glucokinase) in islets of fa/fa rats but had no significant effect in islets of lean rats. The reduced activity was due to altered glucokinase function, because ADX had no significant effect on hexokinase function in either phenotype (data not shown (Fig. 4B) . In lean rats, ADX increased the Vm,x of glucokinase (Table 3 ) but this did not result in any significant change in total phosphorylation of glucose in the physiological range (Fig.4A) . MH was previously shown to have no effect on glucose phosphorylation in islets from fa/fa rats [11] . In this study, MH (10 mmol. 1 1) caused a significant reduction in glucose phosphorylation in ADX but not control fa/fa rat islets (Fig. 5B) . MH inhibited glucokinase activity in both groups of lean rat islets (Fig. 5A) . In both lean rat islets and ADX fa/fa islets the inhibitory effect of MH was due to a twofold increase in the glucokinase K m (Table 3) .
Discussion
Although ADX is known to reduce insulin secretion, its effects on specific beta-cell biochemical pathways have not been reported. In this study we investigated ADX effects on glucose response, glucokinase activity and MH inhibitory actions in isolated islets from both lean and fa/[a rats. ADX reduced glucose sensitivity in the ADX fa/fa rat islets, increasing the ECs0 from 6.1 mmol-1-1 to 10.6 mmol. 1-1, comparable to control lean rat islets. Furthermore, sensitivity of fa/fa rat islets to MH inhibition, which was reduced in all ages of rats tested [17] , was nearly normalized by ADX. In intact adult lean rat islets, 10 mmol. 1-1 MH reduced glucose-induced insulin release by 45 % but produced a non-significant reduction of 29 % in the islets from fa/fa rats [17] . In this study 10 mmol. 1-1 MH significantly reduced glucose-stinmtated insulin release in isolated islets from ADX fa/fa, ADX lean and control lean rats by 48, 57.6 and 58.5 %, respectively but the same dose only produced (-A-) . The number of individual experiments from separate rat donors is as follows: control lean,12; ADX lean, 11; control obese, 10; ADX obese, 6. *p < 0.05 compared with control data a 23 % reduction in fa/fa control islets. The lowest MH concentration producing a significant effect was similar in islets from both ADX fa/fa, ADX lean, and control lean rats (1.0 mlnol. 1-1) with glucose concentrations of 15 mmol 9 1-1 or higher. This study clearly demonstrates that two specific beta-cell lesions related to glucose metabolism, insensitivity to MH and sensitivity to glucose, are dependent on the hypothalamo-pituitary-adrenal (HPA) axis in hyperinsulinaemic obese rats. Because MH competitively inhibits glucokinase it seems likely that the HPA axis is a modulator of glucokinase function in islets.
Our study of glucokinase kinetics supports the notion that normalization of both the glucose and MH sensitivity of the insulin secretory response occur because ADX modifies glucokinase function in fa/fa rats. ADXfa/fa rat islet glucokinase displayed a rightward shift in the K m for glucose, and a further increase in K m upon treatment of the islets with MH, similar to results in lean rat islets. Results in control fa/ fa rat islets confirm our previous results of a leftward shift in the K m and insensitivity to MH compared with lean controls [11] . A role for glucokinase is further supported by earlier results indicating no differ- (Table 3) ence in sensitivity to non-glucidic secretagogues including c~-ketoisocaproic acid, L-arginine, and quinine [9] . Glucokinase is a low-affinity glucose-phosphorylating enzyme found only in liver cells and pancreatic islet beta cells [10] . While the activities of both liver and pancreatic glucokinase isoforms are similar, gene expression of the isoforms is regulated differently because of tissue-specific promoter regions of the gene [28] . Known regulators of islet beta-cell glucokinase expression and activity include glucose [13, 29] , exercise [30] , and starvation [12] . The data obtained in the current study are evidence that pancreatic glucokinase activity is also regulated by the HPA axis but does not indicate whether glucocorticoids directly modulate glucokinase or exert their effects via their influence on the anterior pituitary or hypothalamic nuclei. Results of studies investigating direct glucocorticoid action on insulin secretion or biosynthesis, and on pancreatic glucokinase activity are not conclusive [31] [32] [33] [34] . However, glucocorticoids may increase pancreatic islet beta-cell glucokinase activity indirectly either by increasing glucose production by the liver or by acting through the HPA axis [35, 36] . Developmental studies show that glucokinase mRNA is present in pancreatic tissues of 2-day-old rat pups [37] . Glucocorticoids are detected at very low levels in 6-12-day-old rats, but increase considerably by the end of the second week reaching peak levels by 24 days of age in rats [38] . It is during this period, in 17-21-day-old fa/fa rats, that enhanced parasympathetic nervous system potentiation of glucose-induced insulin secretion in fa/fa rats was observed [5] . ADX performed in 18-day-old fa/fa rats abolished this parasympathetic nervous system effect in the fa/fa rat pancreas but it could be restored by corticosterone replacement within 24 h [20] . Increased parasympathetic nervous system stimulation of glucose-induced insulin release in the fa/fa pancreatic tissue was even observed in 5-day-old pre-obese pups [3] . Although not supported by experimentation to date, one could speculate that glucokinase activity is increased in fa/fa pups even at this early stage. The increased glucokinase activity is probably masked by the high-fat diet during suckling.
ADX or infusion of corticotrophin releasing hormone (CRH) into cerebral ventricles results in body weight loss, reduced food intake, increased sympathetic nervous activity in the periphery and reduced insulin secretion in fa/fa rats and other obese rodents [39] [40] [41] [42] . These observations have led to the hypothesis that the actions of corticosterone in obesity are due to an inhibitory action on central CRH, especially in the hypothalamic nuclei that are involved in the integration of both endocrine and autonomic nervous system function in relation to energy balance [43, 44] . Specifically in the fa/fa rat, it was concluded that lower CRH tone in the hypothalamus is due to defects in regulation of the HPA axis proximal to the region of the CRH system that mediates feedback inhibition of corticosterone secretion because the pituitaryadrenal axis had normal response to a CRH challenge [44] . It then follows that the beta-cell biochemical defects observed in 5-week-old fa/fa rats might be under the control of an already abnormally-regulated HPA axis [45] . How increasing hypothalamic CRH levels modulate peripheral events such as insulin secretion is not precisely known; however, ADX appears to increase sympathetic outflow relative to parasympathetic outflow by a CRH-mediated mechanism [46, 47] . Thus, it is tantalizing to speculate that a deficient sympathetic nervous system in the developing fa/fa rat pancreas causes reversible changes in glucokinase function. This idea is consistent with the data showing that exercise, which also alters sympathetic outflow, can decrease glucokinase activity [30] .
In this study, ADX did not cause the body weight of fa/fa rats to return to the same level as that of lean rats. These results agree with those of other investigators showing that ADX performed at 5 weeks or later does not completely normalize fa/fa rat body weight to that of the lean rats, but reduces the rate of body fat accumulation in the ADX fa/fa rats [23, 48] .
Nor did ADX affect pancreatic islet insulin content in either lean or fa/fa rats. These results concur with those of Fiedorek and Permutt [36] where ADX did not affect proinsulin mRNA levels in 20 % sucrosefed ADX Sprague-Dawley rats, but did reduce proinsulin mRNA in fasted or fed ADX rats without sucrose supplement. In our study both ADX and control rats had unlimited access to NaC1/glucose solution throughout the 15 days post-surgery. Because the control fa/fa rats in this study gained more weight than the ADX fa/fa rats we therefore reached the same conclusion, i.e. that glucocorticoids are not essential for insulin synthesis if the animals have adequate plasma glucose.
In conclusion, changes in pancreatic glucokinase activity are likely to contribute to the development of hyperinsulinaemia in the fa/fa rat. The development of this lesion in the MH response is dependent on the presence of an intact HPA axis, and ADX, in this study, restored pancreatic islet MH sensitivity in isolated islets offa/fa rats.
